Clinical Trial Update: Pediatric Open-Label Extension Study [Phase 3]

View source ↗

Summary

Phase 3 pediatric open-label extension study completed; results posted in 2019 for schizophrenia and autism conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder
• Bipolar Depression
• Schizophrenia

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Schizophrenia, Autism | Phase 3 | Status: COMPLETED | Results posted: 2019-12-19